![macomics new logo.png](https://www.bioindustry.org/static/ad78c3dc-8735-4462-b157ab6a948c09bf/macomics-new-logo.png)
Macomics
Drug Discovery
- Website
- https://macomics.com
- Membership category
- Emerging Y3
137a George Street, Edinbrugh, EH2 4JY, United Kingdom
Macomics at a glance
Macomics is an immuno-oncology company with world-leading expertise in macrophage biology.
About Macomics
Macomics Ltd is an immuno-oncology company with world-leading expertise in macrophage biology, developing precision medicines to modulate macrophages for the treatment of cancer. The company is progressing a diversified portfolio of therapies targeting disease-specific tumour-associated macrophages (‘TAMs’) towards the clinic and has a novel technology platform supporting target discovery and validation.
Macomics was co-founded in 2019 by Prof. Jeffrey Pollard and Dr Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology. It has R&D and office facilities in Edinburgh and Cambridge, UK and is backed by Epidarex Capital, Scottish Enterprise, and Caribou Property Limited.